



Question: What vaccines are available?

Answer: In the U.S., there are three vaccines being administered. The Pfizer/BioNTech and Moderna vaccines are messenger RNA (mRNA) vaccines. These were the first vaccines to become available in the U.S., mostly because so much research had been done to develop this method prior to the pandemic.

So, although these are the first ever mRNA vaccines used in the U.S., this technique has been worked on by scientists since the 1990s. The pandemic brought increased attention and funding that allowed scientists to improve upon this existing technology and make it available. There is currently another mRNA vaccine being used in African countries against the Ebola virus.

The COVID-19 mRNA vaccines are two-doses that deliver one or more coronavirus genes into human cells, essentially giving the body temporary instructions to make harmless spike proteins to stimulate immunity. The vaccine components degrade quickly and do not alter the DNA of the vaccine recipient; but the result is that the body can produce its own antibodies against COVID-19.

The Pfizer/BioNTech mRNA vaccine was approved by the FDA in August 2021 for all people 16 years and older. This approval is the first of its kind for an mRNA vaccine. The Moderna mRNA vaccine was also approved more recently, in January 2022, for adults 18 years and older.

The Pfizer vaccine is also available to 12 to 15-year-olds under an Emergency Use Authorization (EUA). Per the CDC, this vaccine is recommended to all people 12 years and older including those who are pregnant, lactating, trying to become pregnant, or planning to become pregnant soon.

A lower-dose pediatric Pfizer/BioNTech vaccine is currently available to 5 to 11-year-olds under another EUA. At the time of this update, Pfizer has submitted an additional EUA request to the FDA for an even lower-dose vaccine for children ages 6 months to 4 years old. The FDA Advisory Committee is expected to meet and vote on February 15, 2022, which will determine if and when this vaccine will be made available to this younger population.

The third vaccine available is made by Johnson and Johnson and uses the viral vector method. This technology has been used in vaccine development since the 1970s and relies on a harmless virus (the vector) to deliver the vaccine. In the one-dose viral vector COVID-19 vaccines, a gene for the viral spike protein is inserted into another inactive virus to deliver the gene to human cells. This causes the immune system to recognize the virus and quickly respond by producing antibodies.

Use of the Johnson and Johnson vaccine was briefly suspended when data showed an increased risk of a rare adverse event involving low platelet count and blood clots in vaccine recipients under 50 years old who identified as

women. On April 23, 2021, the FDA and CDC recommended that use of the vaccine continue due to benefits outweighing the risks.

Then, on December 16, 2021, the CDC released newer data, showing a higher risk of blood clotting than previously known. Those with the highest risk are people who identify as women between the ages of 30 and 49. The updated risk is 1 per 100,000 people in this demographic. Overall, the rate of the rare blood clotting condition is 3.8 per 1 million people who received this vaccine.²

Data have increasingly shown that the Johnson and Johnson vaccine offers significantly less protection than the available mRNA vaccines. Given this new information, the CDC is now recommending the mRNA vaccines over the Johnson and Johnson viral vector vaccine. The Johnson and Johnson vaccine is not being removed from market in the U.S., and will still be available to anyone who prefers this option.³

Question: How effective are the different vaccines at preventing COVID-19?

Answer: This is a very difficult question to answer due to newly evolving COVID-19 variants and disease distribution. The more contagious a variant is, and the more people who are spreading it, can change the answers to this question.

The current variant, Omicron, is a good example of this. Omicron spreads more easily and is better at infecting fully vaccinated people (called a breakthrough infection) than previous variants. There is not a specific vaccine efficacy estimate for the Omicron variant, but more vaccinated people becoming infected means that vaccine efficacy is lower-and, per the CDC, fully vaccinated people are likely to become infected. However, fully vaccinated people who become infected with Omicron are very unlikely to become seriously ill, be hospitalized, or die from infection. So, although vaccine efficacy is lower, vaccine effectiveness remains high.

These definitions may help you as you read other articles and interpret data:

Vaccine efficacy is defined as the percent decrease in disease incidence in a vaccinated group versus an unvaccinated group in optimal conditions (such as in a randomized control trial).

Vaccine effectiveness measures a vaccine's ability to prevent any undesired outcome such as infection, severe disease, hospitalization, or death in real world conditions.

With the original virus that causes COVID-19, vaccine efficacy was shown to be around 95% for the mRNA vaccines (Pfizer BioNTech and Moderna) and 72% for the viral vector vaccine (Johnson and Johnson). These numbers captured how the vaccines performed under the controlled conditions of a clinical trial, which differs from the vaccines' real-world effectiveness and does not account for factors such as newer variants, vaccine response in different people, and how protection may lessen or change over time.





For more information on this topic, including the latest information on vaccine efficacy and effectiveness, visit:

[Omicron Variant-CDC](https://bit.ly/34Jzeab) (<https://bit.ly/34Jzeab>)

[Yale Medicine Vaccine Article](https://bit.ly/3pxvBNO) (<https://bit.ly/3pxvBNO>)

Question: What is the available evidence on COVID-19 vaccination in pregnancy and while lactating?

Answer: The CDC tracks pregnant people who receive a COVID-19 vaccine and, as of January 31, 2022, there were 194,531 self-reported pregnant people who completed the CDC's "v-safe after vaccination health checker." Of this group, 14,998 vaccinated pregnant people enrolled in the "v-safe pregnancy registry" to be followed throughout their pregnancies and beyond. In this group, there was no significant increase in the rate of pre-term birth, miscarriage, placental abnormalities, or congenital anomalies compared to the general population. So far, most v-safe pregnancy registry participants received their vaccines in the third trimester of pregnancy.⁴

Here is a link to the CDC's '[COVID-19 Vaccines While Pregnant or Breastfeeding](#)' page:

<https://bit.ly/3oFhT9v>

Researchers are continuing to publish many smaller studies about vaccination in lactating people. Early data show that antibodies to the COVID-19 virus successfully transfer from vaccinated parents to babies who are ingesting human milk. Small studies have also demonstrated that, while antibodies do successfully transfer, the components of the mRNA COVID-19 vaccines do not transfer via human milk.⁶ While this research is encouraging, and in line with other vaccines given during pregnancy, more information is needed to determine if the antibodies transferred in human milk and cord blood sufficiently protect babies from COVID-19.

Question: Are the vaccines approved for use during pregnancy?

Answer: In response to the growing body of evidence demonstrating the safety of COVID-19 vaccines for pregnant and lactating people, many major organizations began recommending vaccination for this population in August 2021. This list currently includes the Federal Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), American College of Obstetricians and Gynecologists (ACOG), American College of Nurse-Midwives (ACNM), the Society for Maternal-Fetal Medicine (SMFM), and the National Institute for Health and Care Excellence in the United Kingdom (NICE), among others.

Question: Does COVID-19 cause more serious disease in pregnancy? What are the known risks of vaccinating during pregnancy compared to the known risks of COVID-19 during pregnancy?

Answer: It is known that pregnant people with SARS-CoV-2 infection are at higher risk for more severe disease—especially for those who are unvaccinated. A study by the National Institute of Health Research (NIHR) showed that 99.5% of pregnant people admitted to the hospital with COVID-19 were unvaccinated. When compared with non-pregnant people, pregnant people with COVID-19 were at an increased risk of intensive care admission, respiratory support, and pneumonia.⁷

A large, population-based study from Scotland that was published in January 2022 provides additional information about the different outcomes for vaccinated and unvaccinated pregnant people who were infected with SARS-CoV-2. In this study, researchers looked at 87,964 pregnant people, 4,950 of which had confirmed SARS-CoV-2 infections. The study period began in December 2020 and ended before booster doses were routinely available. The predominant variants at the time were Alpha and Delta.

In the study group, 77.4% of all SARS-CoV-2 infections in pregnancy were among the unvaccinated. Among those infected, being vaccinated was linked with significantly decreased hospitalization and critical care admission. Vaccinated pregnant people were admitted to the hospital at a rate of 5.1% and to a critical care unit at a rate of 0.2%; unvaccinated pregnant people were admitted to the hospital at a rate of 19.5% and to a critical care unit at a rate of 2.7%. All of the perinatal deaths (defined as stillbirths or newborn death within the first 28 days of life) that occurred in the study after SARS-CoV-2 infection took place among the unvaccinated. In this group, there were 19 deaths out of 2,364 births. There were zero perinatal deaths among the vaccinated and infected group. While the researchers did not have access to detailed medical records regarding the perinatal deaths, 14 of the 19 deaths occurred within 28 days of active infection. The rate of perinatal mortality in the study was 22.6 per 1000 in the vaccinated group and 5.6 per 1000 in the unvaccinated group.⁸

Two other known risks of COVID-19 in pregnancy are preterm birth and preeclampsia. In 2021, researchers analyzed California Vital Statistics birth certificate records of more than 200,000 births and found a 60% increased risk in very pre-term birth (giving birth at <32 weeks of pregnancy) in participants with a COVID-19 diagnosis. Additionally, there was a 40% increased risk in pre-term birth (giving birth at <36 weeks of pregnancy), and a 10% increased risk in early term birth (giving birth between 37 weeks 0 days and 38 weeks 6 days of pregnancy) in participants with a COVID-19 diagnosis. These increased risks are relative to the control or non-COVID-19 group.⁹

Also in 2021, researchers reviewed 28 different studies made up of 790,954 pregnant people, 15,524 of which were diagnosed with COVID-19. The risk of developing preeclampsia was 1.58 times higher in the COVID-19 group as compared to the pregnant people without COVID-19. Both symptomatic and asymptomatic COVID-19 infections





resulted in significantly higher rates of preeclampsia, though the rate was slightly higher in symptomatic cases.¹⁰

Another study, currently published as a letter to the editor on October 20, 2021, in the New England Journal of Medicine, looked at the early (first trimester) miscarriage rate in pregnant people who received a COVID-19 vaccine during pregnancy and pregnant people who did not. The study took place in Norway and researchers reviewed the records of about 18,000 pregnant people—about 14,000 of whom had ongoing pregnancies and about 4,000 of whom had early miscarriages—from Norwegian registry data. The study found no evidence of increased early pregnancy loss in the participants who received a COVID-19 vaccine, adding to the increasing evidence of the safety of COVID-19 vaccines in pregnancy.¹¹

Question: Has research demonstrated a link between COVID-19 and infertility?

Answer: There is no evidence that demonstrates a link between COVID-19 vaccination and infertility for egg carriers. Theories about a possible connection come from what some believe is a structural similarity of the SARS-CoV-2 spike protein and syncytin-1, a protein that helps form the placenta and is necessary for the development of an embryo in utero. This misleading theory, circulated by a known anti-vaccination group, proposed that an immune response against the spike protein could also cause an immune response against syncytin-1, thus potentially impacting pregnancy. However, experts in immunology, infectious disease, and pregnancy have refuted this idea.

A study published in September 2021 studied this idea in people already undergoing in vitro fertilization for fertility treatment. Study participants were divided into three groups: 1) those who had COVID-19 antibodies from prior natural infection, 2) those who had COVID-19 antibodies from prior vaccination, and 3) those who did not have antibodies from infection or vaccination. All vaccinated participants received one of the two available mRNA vaccine regimens. In the study, 143 unique frozen embryo transfers (FETs) were analyzed. Standard screening and protocols for FET were followed. The researchers found no difference in pregnancy success rates between the three groups.¹²

Another study explored this theory by directly comparing the placentas of birthing people who had received the COVID-19 mRNA vaccine in pregnancy versus those who had not received the vaccine. In this study, researchers at Northwestern University examined the placentas of 84 vaccinated people and 116 unvaccinated people shortly after giving birth. All study participants had negative COVID-19 polymerase chain reaction (PCR) tests. The vaccinated group did not have a higher rate of placental abnormalities as compared to the unvaccinated group. The study, published in Obstetrics and Gynecology in August 2021, further refutes theories of any association between COVID-19 vaccines and

placental health, and adds to the growing body of evidence that COVID-19 mRNA vaccines are safe in pregnancy and the preconception period.¹³

Another much discussed topic regarding fertility is the possible association between COVID-19 vaccination and changes in menstrual cycles. The United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has received over 30,000 reports of such events to their yellow card surveillance system—a self-reporting system similar to VAERS in the United States. Reproductive health experts suggest that these changes are likely hormonal and the result of the body's immune response from vaccination, rather than a reaction to specific components of the vaccine. These reports have come from both mRNA and viral vector vaccine recipients, and most people who reported these changes had their abnormal menstrual cycles return to normal after one cycle. More research is needed to investigate this possible link. For anyone tracking their menstrual cycles in hopes of preventing or achieving pregnancy, this is a potentially important consideration.¹⁴

A study published recently in the American Journal of Epidemiology is the first to suggest a link between SARS-CoV-2 infection and a temporary decrease in male fertility. In this study, researchers looked back in time at the medical records of over 2000 couples who identified as male-female that were trying to conceive without fertility treatments. As other studies have also shown, in this group there were no major differences in conception rates between vaccinated and unvaccinated study participants. However, in couples where natural SARS-Cov-2 infection had occurred in the male partner within 60 days of a given menstrual cycle, couples were 18% less likely to conceive during that cycle. The decreased male fertility was temporary, and researchers believe could be due to lower sperm count and motility (movement) caused by fever—a common symptom of SARS-CoV-2 infection.¹⁵

Question: What can we expect in terms of future research about vaccination in pregnancy?

Answer: A study called “Preg-CoV” is the first randomized trial to directly study COVID-19 vaccination in pregnancy. The study is currently taking place in the United Kingdom at the National Institute of Health Research (NIHR) Southampton Clinical Research Facility and is enrolling pregnant people between the ages of 18-44 and in weeks 13-34 of pregnancy. The primary goal of the study is to determine the best timing between doses for the mRNA COVID-19 vaccines in pregnancy. Study scientists will analyze blood and human milk samples from pregnant study participants, as well as blood samples from babies born to study participants. Scientists hope the results will help us understand how vaccines protect pregnant people and how that protection can potentially transfer to newborns. The study is still open to enrollment.¹⁶





Question: Is there a new recommendation regarding booster shots for pregnant people?

Answer: In September 2021, the FDA announced an Emergency Use Authorization (EUA) for booster doses of the Pfizer/BioNTech vaccine. Another EUA for Moderna and Johnson and Johnson booster doses followed shortly after in October 2021. This approval also allowed for the mixing of vaccines, such that the booster dose may be a different brand than the primary vaccine dose(s).¹⁷ At first, only more vulnerable populations including people over 65, immunocompromised individuals, and people living or working in high-risk environments were approved to receive booster doses.

On December 9, 2021, the recommendation was extended to all people 18 years and older and on January 5, 2022, to all people 12 years and older. Per a webinar that we attended, taught by Kara Polen at the CDC, this recommendation includes pregnant and lactating people as well as those

wanting to become pregnant soon.¹⁸ The American College of Obstetricians and Gynecologists (ACOG) also updated their Practice Advisory on December 3, 2021 to include pregnant and recently pregnant people in their booster dose recommendation.¹⁹

To summarize, at this time, booster doses are available to anyone 12 years and older. The Pfizer/BioNTech vaccine is the only option approved for 12 to 17-year-olds. All available brands can be given to those 18 years and older. The CDC updated their guidance on December 17, 2021, recommending the mRNA vaccines over the Johnson and Johnson option. You can view the CDC's guide on boosters here:

[COVID-19 Vaccine Booster Shots](https://bit.ly/3HLxZG7) (<https://bit.ly/3HLxZG7>)

A NOTE FROM EBB

The research on vaccines (including the research on booster doses) is rapidly changing, and new studies may be published that update some of the current evidence written about in this handout. Below is a list of resources that may be helpful to pregnant people and those trying to conceive in navigating vaccination decisions:

- [COVID-19 and Pregnancy CDC Page](https://bit.ly/3mevXGn) (<https://bit.ly/3mevXGn>)
- [NIH-How COVID-19 Affects Pregnancy](https://bit.ly/3pL1OQO) (<https://bit.ly/3pL1OQO>)
- [Preg-CoV Trial Information](https://bit.ly/3bd2dmE) (<https://bit.ly/3bd2dmE>)

Disclaimer & Copyright:

This information does not substitute for a care provider-patient relationship and should not be relied on as personal medical advice. Any information should not be acted upon without professional input from one's own healthcare provider. © 2022. All rights reserved. Evidence Based Birth® is a registered trademark. Permission is granted to reproduce this handout in print as long as only the most recently updated version is used and complete credit given to the authors. Handouts may be distributed freely in print but not sold. This PDF may not be posted online.

1. CDC Press Release. CDC Recommends Use of Johnson and Johnson's Janssen COVID-19 Vaccine Resume. Updated online August 27, 2021.
2. Astor Maggie, Otterman Sharon. Covid News: Citing Rare Blood Clot Risk, C.D.C. Discourages Johnson & Johnson Vaccine. The New York Times. Updated online December 17, 2021.
3. CDC Media Statement. CDC Endorses ACIP's Updated COVID-19 Vaccine Recommendations. Updated online December 16, 2021.
4. CDC Website. COVID-19 Vaccines While Pregnant or Breastfeeding. Updated online January 28, 2022.
5. Gray K., Bordt E., Atyeo C., et al. (2021). COVID-19 vaccine response in pregnant and lactating women: a cohort study. *AJOG*. 2021 Mar 25.
6. Golan Yarden, Prah Mary, Cassidy Arianna, et al. (2021). Evaluation of Messenger RNA From COVID-19 BTN162b2 and mRNA-1273 Vaccines in Human Milk. *JAMA Pediatrics*. 2021 Oct.
7. Vousden Nicola, Ramakrishnan Rema, Bunch Kathryn, et al. (2021). Impact of SARS-CoV-2 variant on the severity of maternal infection and perinatal outcomes: Data from the UK Obstetric Surveillance System national cohort. *medRxiv*. [preprint]
8. Stock Sarah, Carruthers Jade, Calvert Clara, et al. (2022). SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland. *Nature Medicine*. 2022 February 04.
9. Karasek Deborah, Baer Rebecca, McLemore Monica R, et al. (2021). The Association of COVID-19 Infection in Pregnancy with Preterm Birth: A Retrospective Cohort Study in California. *The Lancet Regional Health-Americas*. 2021 July 30.
10. Conde-Agudelo Agustin, Romero Roberto (2021). SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis. *American Journal of Obstetrics and Gynecology*. 2021 July 21.
11. Magnus Maria, Gjessing Hakon, Eide Helena, et al. (2021). Covid-19 Vaccination during Pregnancy and First-Trimester Miscarriage [letter to the editor]. *New England Journal of Medicine*. 2021 Oct 20.
12. Morris, Randy (2021). SARS-CoV-2 spike protein seropositivity from vaccination or infection does not cause sterility. *F & S Reports*. 2021 Sep.
13. Shanes Elisheva, Otero Sebastian, Mithal Leena, et al. (2021). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Pregnancy Measures of Immunity and Placental Histopathology. *Obstetrics and Gynecology*. 2021 Aug.
14. Male, Victoria (2021). Menstrual Changes After COVID-19 Vaccination. *BMJ*. 2021 Sep 16.
15. Wesselink Amelia, Hatch Elizabeth, Rothman Kenneth, et al. (2022). A prospective cohort study of COVID-19 vaccination, SARS-CoV-2 infection, and fertility. *American Journal of Epidemiology*. 20 January 2022.
16. New study into COVID-19 vaccine dose interval for pregnant women launches in Southampton. University of Southampton News. Published online August 7, 2021
17. FDA Press Release. FDA Takes Additional Actions on the Use of a Booster Dose for COVID-19 Vaccines. Updated online October 20, 2021.
18. Polen, Kara. (2021). Pregnant During a Pandemic: Updates on COVID-19 and Vaccination During Pregnancy. [Power Point Presentation]. COVID-19 Vaccines & Pregnancy & Lactation: What Midwives Need to Know, National Association of Certified Professional Midwives, virtual conference.
19. ACOG Practice Advisory. COVID-19 Vaccination Considerations for Obstetric-Gynecologic Care. Updated online December 3, 2021.

